ChemGenex on a roll
Tuesday, 01 July, 2008
ChemGenex [ASX: CXS] has submitted the non-clinical section of its New Drug Application [NDA] to the US FDA for omacetaxine, the company's chronic myeloid leukaemia treatment.
The non-clinical section is the first of three in the company's rolling submission: the next steps are the chemistry and manufacturing controls segment and the clinical section.
ChemGenex expects that both remaining submissions will be complete by mid-2009.
The FDA has already granted fast-track designation to the drug, omacetaxine mepesuccinate, for treatment of patients who have failed prior treatment with Novartis' imatinib mesylate, or Glivec.
You may age faster if your dad smoked during puberty
Researchers found that people whose fathers began smoking during puberty (at age 15 or younger)...
How an autism-linked mutation alters social behaviour
Until now, the Shank3 gene had been associated with autism, but the biological mechanism...
Studies provide hope for more protective COVID vaccines
A protein particle hidden within the SARS-CoV-2 virus could lead to longer-lasting, more...
